-+ 0.00%
-+ 0.00%
-+ 0.00%

Oncotelic Therapeutics reports publication on Deciparticle technology supporting Sapu003 development

PUBT·07/22/2026 13:30:28
Listen to the news
Oncotelic Therapeutics reports publication on Deciparticle technology supporting Sapu003 development
  • Oncotelic flagged a peer-reviewed Biomedicines publication validating Deciparticle technology supporting Sapu003, its intravenous everolimus program.
  • Study package covers ADME, pharmacokinetics, tissue distribution, GLP toxicology, cGMP manufacturing; supports ongoing Phase 1 trial in advanced solid tumors.
  • Preclinical results showed broad systemic distribution with reduced gastrointestinal exposure versus oral everolimus, no treatment-related gastric pathology in repeat-dose studies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220930PRIMZONEFULLFEED9766227) on July 22, 2026, and is solely responsible for the information contained therein.